Cargando…

PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model

BACKGROUND: The phosphoinositide 3-kinase (PI3K) signaling pathway is an interesting target in cancer treatment. The awareness of the proarrhythmic risk of PI3K inhibitors was raised because PI3K is also involved in regulating signaling toward cardiac ion channels. Canine cardiomyocytes treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: van Bavel, J. J. A., Pham, C., Beekman, H. D. M., Houtman, M. J. C., Bossu, A., Sparidans, R. W., van der Heyden, M. A. G., Vos, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381882/
https://www.ncbi.nlm.nih.gov/pubmed/35990966
http://dx.doi.org/10.3389/fcvm.2022.956538
_version_ 1784769174130655232
author van Bavel, J. J. A.
Pham, C.
Beekman, H. D. M.
Houtman, M. J. C.
Bossu, A.
Sparidans, R. W.
van der Heyden, M. A. G.
Vos, M. A.
author_facet van Bavel, J. J. A.
Pham, C.
Beekman, H. D. M.
Houtman, M. J. C.
Bossu, A.
Sparidans, R. W.
van der Heyden, M. A. G.
Vos, M. A.
author_sort van Bavel, J. J. A.
collection PubMed
description BACKGROUND: The phosphoinositide 3-kinase (PI3K) signaling pathway is an interesting target in cancer treatment. The awareness of the proarrhythmic risk of PI3K inhibitors was raised because PI3K is also involved in regulating signaling toward cardiac ion channels. Canine cardiomyocytes treated with PI3K inhibitors show an increased action potential duration and reduced cardiac repolarizing currents. Now, the potential proarrhythmic effect of chronic treatment of PI3K/mTOR inhibitor GSK2126458 (omipalisib) was investigated in the atrioventricular (AV) block dog model. METHODS: Purpose-bred Mongrel dogs received complete AV block by ablation of the bundle of His and their hearts were paced in the right ventricular apex at VDD-mode (RVA-VDD). In this way, sinus rhythm was maintained for 15 ± 1 days and thereby bradycardia-induced cardiac remodeling was prevented. Dogs received 1 mg/kg omipalisib once (n = 3) or twice (n = 10) a day via oral administration for 7 days. Under standardized conditions (anesthesia, bradycardia at 60 beats/min, and a dofetilide challenge), potential proarrhythmic effects of omipalisib were investigated. RESULTS: Twice daily dosing of omipalisib increased accumulative plasma levels compared to once daily dosing accompanied with adverse events. Omipalisib prolonged the QT interval at baseline and more strongly after the dofetilide challenge (490 ± 37 to 607 ± 48 ms). The arrhythmic outcome after omipalisib resulted in single ectopic beats in 30% of dogs perpetuating in multiple ectopic beats and TdP arrhythmia in 20% of dogs. Isolated ventricular cardiomyocytes from omipalisib-treated dogs showed a diminished I(Ks) current density. CONCLUSION: Chronic treatment of PI3K/mTOR inhibitor omipalisib prolonged the QT interval in a preclinical model under standardized proarrhythmic conditions. Furthermore, this study showed that electrical remodeling induced by omipalisib had a mild proarrhythmic outcome.
format Online
Article
Text
id pubmed-9381882
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93818822022-08-18 PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model van Bavel, J. J. A. Pham, C. Beekman, H. D. M. Houtman, M. J. C. Bossu, A. Sparidans, R. W. van der Heyden, M. A. G. Vos, M. A. Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: The phosphoinositide 3-kinase (PI3K) signaling pathway is an interesting target in cancer treatment. The awareness of the proarrhythmic risk of PI3K inhibitors was raised because PI3K is also involved in regulating signaling toward cardiac ion channels. Canine cardiomyocytes treated with PI3K inhibitors show an increased action potential duration and reduced cardiac repolarizing currents. Now, the potential proarrhythmic effect of chronic treatment of PI3K/mTOR inhibitor GSK2126458 (omipalisib) was investigated in the atrioventricular (AV) block dog model. METHODS: Purpose-bred Mongrel dogs received complete AV block by ablation of the bundle of His and their hearts were paced in the right ventricular apex at VDD-mode (RVA-VDD). In this way, sinus rhythm was maintained for 15 ± 1 days and thereby bradycardia-induced cardiac remodeling was prevented. Dogs received 1 mg/kg omipalisib once (n = 3) or twice (n = 10) a day via oral administration for 7 days. Under standardized conditions (anesthesia, bradycardia at 60 beats/min, and a dofetilide challenge), potential proarrhythmic effects of omipalisib were investigated. RESULTS: Twice daily dosing of omipalisib increased accumulative plasma levels compared to once daily dosing accompanied with adverse events. Omipalisib prolonged the QT interval at baseline and more strongly after the dofetilide challenge (490 ± 37 to 607 ± 48 ms). The arrhythmic outcome after omipalisib resulted in single ectopic beats in 30% of dogs perpetuating in multiple ectopic beats and TdP arrhythmia in 20% of dogs. Isolated ventricular cardiomyocytes from omipalisib-treated dogs showed a diminished I(Ks) current density. CONCLUSION: Chronic treatment of PI3K/mTOR inhibitor omipalisib prolonged the QT interval in a preclinical model under standardized proarrhythmic conditions. Furthermore, this study showed that electrical remodeling induced by omipalisib had a mild proarrhythmic outcome. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9381882/ /pubmed/35990966 http://dx.doi.org/10.3389/fcvm.2022.956538 Text en Copyright © 2022 van Bavel, Pham, Beekman, Houtman, Bossu, Sparidans, van der Heyden and Vos. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
van Bavel, J. J. A.
Pham, C.
Beekman, H. D. M.
Houtman, M. J. C.
Bossu, A.
Sparidans, R. W.
van der Heyden, M. A. G.
Vos, M. A.
PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model
title PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model
title_full PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model
title_fullStr PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model
title_full_unstemmed PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model
title_short PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model
title_sort pi3k/mtor inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the av block dog model
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381882/
https://www.ncbi.nlm.nih.gov/pubmed/35990966
http://dx.doi.org/10.3389/fcvm.2022.956538
work_keys_str_mv AT vanbaveljja pi3kmtorinhibitoromipalisibprolongscardiacrepolarizationalongwithamildproarrhythmicoutcomeintheavblockdogmodel
AT phamc pi3kmtorinhibitoromipalisibprolongscardiacrepolarizationalongwithamildproarrhythmicoutcomeintheavblockdogmodel
AT beekmanhdm pi3kmtorinhibitoromipalisibprolongscardiacrepolarizationalongwithamildproarrhythmicoutcomeintheavblockdogmodel
AT houtmanmjc pi3kmtorinhibitoromipalisibprolongscardiacrepolarizationalongwithamildproarrhythmicoutcomeintheavblockdogmodel
AT bossua pi3kmtorinhibitoromipalisibprolongscardiacrepolarizationalongwithamildproarrhythmicoutcomeintheavblockdogmodel
AT sparidansrw pi3kmtorinhibitoromipalisibprolongscardiacrepolarizationalongwithamildproarrhythmicoutcomeintheavblockdogmodel
AT vanderheydenmag pi3kmtorinhibitoromipalisibprolongscardiacrepolarizationalongwithamildproarrhythmicoutcomeintheavblockdogmodel
AT vosma pi3kmtorinhibitoromipalisibprolongscardiacrepolarizationalongwithamildproarrhythmicoutcomeintheavblockdogmodel